CR-1-31-B NEW
| Price | $3680 |
| Package | 25mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2025-10-27 |
Product Details
| Product Name: CR-1-31-B | CAS No.: 1352914-52-3 |
| Supply Ability: 10g | Release date: 2025/10/27 |
Product Introduction
Bioactivity
| Name | CR-1-31-B |
| Description | CR-1-31-B, a synthetic rocaglate, acts as a highly potent inhibitor of eIF4A. By disrupting the interaction between eIF4A and RNA, it effectively obstructs the initiation phase of protein synthesis. Specifically, CR-1-31-B interferes with the association between Plasmodium falciparum eIF4A (PfeIF4A) and RNA. Additionally, CR-1-31-B induces apoptosis in neuroblastoma and gallbladder cancer cells [4]. |
| In vitro | CR-1-31-B (100 nM; 24 hours) inhibits MUC1-C translation in EGF-stimulated MCF-10A cells and decreases MUC1-C abundance in MDA-MB-468 breast cancer cells. It sensitizes gallbladder cancer cells to TRAIL-mediated apoptosis by downregulating c-FLIP at the translational level. Neuroblastoma (NB) cell lines show decreased viability, increased apoptosis, and altered cell cycle distribution when treated with CR-1-31-B (24-72 hours), clamping eIF4A and eIF4F onto mRNA to block translation. Additionally, CR-1-31-B (100 nM; 5 hours) enhances reverse glutamine metabolism in pancreatic cancer cells. In viability assays, SH-SY5Y cells and Kelly cells treated with concentrations of 0.1-100 nM for 24-72 hours exhibit significant decreases in viability, with IC50 values of 20 nM for SH-SY5Y and 4 nM for Kelly cells at 48 hours. Apoptosis analysis reveals that CR-1-31-B induces apoptosis in SH-SY5Y cells (10, 20, 50 nM) and Kelly cells (1, 5, 10 nM) over 24-72 hours. |
| In vivo | CR-1-31-B, administered intraperitoneally (IP) at a dosage of 2 mg/kg in 60 μL of olive oil once every two days over 28 days, effectively reduces growth and induces TRAIL-mediated apoptosis in gallbladder cancer cells (GBC) within a BALB/c nude mouse model[2]. Additionally, at a lower dosage of 0.2 mg/kg IP daily for 7 days in a murine orthotopic transplant model of pancreatic ductal adenocarcinoma, CR-1-31-B significantly inhibits protein synthesis and tumor growth in pancreatic cancers[5]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Keywords | CR-1-31-B | CR131B | CR 1 31 B |
| Inhibitors Related | Stavudine | Cysteamine hydrochloride | Sodium 4-phenylbutyrate | Metronidazole | Citric Acid Triammonium | Tributyrin | L-Methionine | Sodium citrate | Cystamine dihydrochloride | L-Ascorbic acid sodium salt | Alginic acid | Dextran sulfate sodium salt (MW 5000) |
Company Profile Introduction
TargetMol Chemicals Inc. is headquartered in Boston, MA, and specializes in products and services that serve the research needs of chemical and biological scientists worldwide. With a client base in 40+ countries, TargetMol has evolved into one of the biggest global research suppliers for compound libraries and small molecule compounds.
170+ Compound Libraries， 10000+ Noval Small Molecucles，16000+ Nature Compounds
TargetMol diligently updates and offers over 170 types of compound libraries and a wide range of high-quality research chemicals, including inhibitors, activators, natural products, peptides, antibodies , and novel life-science kits for laboratory and scientific use. In addition, our lab allows us to conduct CADD (computer-aided drug design) and chemical synthesis to meet the customization needs of our clients.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $5.00/1Box |
VIP1Y
|
Hebei Jiafan Trading Company Limited
|
2024-12-23 | |
| $0.00/200kg |
VIP2Y
|
Qingdao RENAS Polymer Material Co., Ltd.
|
2024-07-19 | |
| $0.00/1box |
VIP1Y
|
Shanghai Yimeixin Technology Co., LTD
|
2025-09-24 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, Massachusetts, USA
INQUIRY